Cargando…
Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study
BACKGROUND: Patient-reported outcomes are increasingly used in the management of patients with multiple sclerosis to understand the patient's perspective of disease and treatment. These measures provide insights into important factors including treatment satisfaction, physical and psychological...
Autores principales: | Wray, Sibyl, Jacques, Francois, Miller, Tamara A, Nicholas, Jacqueline A, Arroyo, Rafael, Travis, Lori, Khatri, Bhupendra, Chirieac, Magdalena, Gandhi, Roopali, Roesch, Nora, Rodrigues, Amelie, Melas-Melt, Lydie, Rawlings, Andreea M, Hunter, Samuel F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669692/ https://www.ncbi.nlm.nih.gov/pubmed/36407472 http://dx.doi.org/10.1177/20552173221135888 |
Ejemplares similares
-
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
por: Coles, Alasdair J., et al.
Publicado: (2023) -
Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial
por: Bolli, Geremia B., et al.
Publicado: (2020) -
Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
por: Van Wijmeersch, Bart, et al.
Publicado: (2019) -
Infection risk with alemtuzumab decreases over time: pooled analysis
of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the
CAMMS03409 extension study
por: Wray, Sibyl, et al.
Publicado: (2018) -
Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
por: Havrdova, Eva, et al.
Publicado: (2017)